antibody

AMPK alpha (AMP-Activated Protein Kinase alpha), phosphorylated (Thr172)

A1475-25A1

100 ul

monoclonal

domestic rabbit

nonconjugated

phosphorylated

10A1(40H9)

AMPK alpha (AMP-Activated Protein Kinase alpha), phosphorylated (Thr172)

rabbit

Mab

Phosphorylated

Antibodies

100 ul

10A1(40H9)

IgG

AMP-activated protein kinase (AMPK) is highly conserved from yeast to plants and animals and plays a key role in the regulation of energy homeostasis. AMPK is a heterotrimeric complex composed of a catalytic a subunit and regulatory beta and gamma subunits, each of which is encoded by two or three distinct genes (a1, 2; b1, 2; g1, 2, 3). The kinase is activated by an elevated AMP/ATP ratio due to cellular and environmental stress, such as heat shock, hypoxia and ischemia. The tumor suppressor LKB1, in association with accessory proteins STRAD and MO25, phosphorylates AMPKa at Thr172 in the activation loop and this phosphorylation is required for AMPK activation. AMPKa is also phosphorylated at Thr258 and Ser485 (for a1; Ser491 for a2). The upstream kinase and the biological significance of these phosphorylation events have yet to be elucidated. The b1 subunit is post-translationally modified by myristoylation and multi-site phosphorylation including Ser24/25, Ser96, Ser101, Ser108 and Ser182. Phosphorylation at Ser108 of the b1 subunit seems to be required for the activation of AMPK enzyme, while phosphorylation at Ser24/25 and Ser182 affects AMPK localization. Several mutations in AMPKg subunits have been identified, most of which are located in the putative AMP/ATP binding sites. Mutations at these sites lead to reduction of AMPK activity and cause glycogen accumulation in heart or skeletal muscle. Accumulating evidence indicates that AMPK not only regulates the metabolism of fatty acids and glycogen, but also modulates protein synthesis and cell growth through EF2 and TSC2/mTOR pathways, as well as blood flow via eNOS/nNOS. Applications: Suitable for use in Western Blot, Immunohistochemistry and Immunoprecipitation. Other applications have not been tested. Recommended Dilution: Western Blot: 1:1000, incubate membrane with diluted antibody in 5% nonfat dry milk, 1X TBS, 0.1% Tween-20 at 4°C with gentle shaking, overnight. Immunohistochemistry (Paraffin): 1:100. Use citrate as an unmasking buffer. Immunoprecipitation: 1:50 Optimal dilutions to be determined by the researcher. Storage and Stability: May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 12 months after receipt. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Dr Hm Hu Mk Mo Rt Ye

Synthetic phospho-peptide corresponding to residues surrounding Thr172 of human AMPKa. Species Sequence Homology: chicken and bovine

Recognizes endogenous human AMPKa only when phosphorylated at threonine 172. Detects both alpha-1 and alpha-2 isoforms of the catalytic subunit. Does not detect the regulatory beta or gamma subunits. Species Crossreactivity: mouse, rat, monkey, S. cerevisiae, D. melanogaster and hamster.

Purified

Supplied as a liquid in 10mM sodium HEPES, pH 7.5, 150mM sodium chloride, 0.1mg/ml BSA, 0.02% sodium azide, 50% glycerol.

Not Determined

Product Type: Mab Isotype: IgG Clone No: 10A1(40H9) Host: rabbit Source: human Concentration: Not Determined Form: Supplied as a liquid in 10mM sodium HEPES, pH 7.5, 150mM sodium chloride, 0.1mg/ml BSA, 0.02% sodium azide, 50% glycerol. Purity: Purified Immunogen: Synthetic phospho-peptide corresponding to residues surrounding Thr172 of human AMPKa. Species Sequence Homology: chicken and bovine Specificity: Recognizes endogenous human AMPKa only when phosphorylated at threonine 172. Detects both alpha-1 and alpha-2 isoforms of the catalytic subunit. Does not detect the regulatory beta or gamma subunits. Species Crossreactivity: mouse, rat, monkey, S. cerevisiae, D. melanogaster and hamster. Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.

IHC IP WB

-20°C

1. Hardie, D.G. (2004) J Cell Sci 117, 5479-87. 2. Carling, D. (2004) Trends Biochem Sci 29, 18-24. 3. Hawley, S.A. et al. (1996) J Biol Chem 271, 27879-87. 4. Lizcano, J.M. et al. (2004) EMBO J 23, 833-43. 5. Shaw, R.J. et al. (2004) Proc Natl Acad Sci USA 101, 3329-35. 6. Woods, A. et al. (2003) J Biol Chem 278, 28434-42. 7. Warden, S.M. et al. (2001) Biochem J 354, 275-83. 8. Kim, E.K. et al. (2004) J Biol Chem 279, 19970-6. 9. Hadad, S.M. et al. (2009) BMC Cancer 9, 307.

https://usbio-images.r.worldssl.net/prodimages/23/A1475-25A1_1.jpg